Related Experiment Videos

2-deoxycoformycin in the treatment of T-large granular lymphocyte leukemia

Panagiotis Tsirigotis1, Evangelos Venetis, Violeta Kapsimali

  • 1Third Department of Internal Medicine, First Hospital of Athens, Social Insurance Foundation, Zaimi Street-Melissia, 15127 Athens, Greece. tsirsi1@otenet.gr

Leukemia Research
|June 14, 2003
PubMed

Insights

A patient with T-large granular lymphocyte leukemia experienced neutropenia. Treatment with 2-deoxycoformycin (DCF) successfully corrected neutrophil counts, demonstrating DCF

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • T-large granular lymphocyte leukemia (T-LGL) is a rare lymphoproliferative disorder.
  • Neutropenia is a common complication, increasing infection risk.
  • Effective treatment strategies for T-LGL-associated neutropenia are crucial.

Observation:

  • A 52-year-old woman presented with agranulocytosis and lymphocytosis.
  • Immunophenotyping confirmed T-large granular lymphocyte leukemia.
  • TCR-Vbeta repertoire analysis revealed restricted Vbeta9 expression, and PCR confirmed clonal TCRgamma-chain gene rearrangement.

Findings:

  • Standard treatments including G-CSF, cyclosporine, methylprednisolone, and methotrexate were ineffective for neutropenia.
  • Treatment with 2-deoxycoformycin (DCF) led to complete resolution of neutropenia.
  • Flow cytometric analysis of the TCR-Vbeta repertoire effectively monitored therapeutic response and residual disease.

Implications:

  • 2-deoxycoformycin (DCF) is a potential therapeutic option for refractory T-LGL-associated neutropenia.
  • TCR-Vbeta repertoire analysis is a valuable tool for assessing treatment efficacy in T-LGL.
  • Early diagnosis and targeted therapy can improve outcomes for patients with T-LGL.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...